Amino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The Same Patents (Class 424/185.1)
-
Patent number: 9439943Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.Type: GrantFiled: September 3, 2015Date of Patent: September 13, 2016Assignee: Ipsen Pharma S.A.S.Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
-
Patent number: 9433923Abstract: The present invention relates to a novel non-cross linked chromatography media provided with glutathione ligands which may or may not be provided with magnetic particles. The chromatography media is used for production of an affinity media provided with gluthatione ligands for adsorption of GST-tagged proteins.Type: GrantFiled: June 11, 2013Date of Patent: September 6, 2016Assignee: GE HEALTHCARE BIO-SCIENCES ABInventors: Gunnar Glad, Therese Graner, Nils Norrman
-
Patent number: 9415101Abstract: This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° C. that can be produced at remarkably low costs. This invention describes novel vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said novel vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.Type: GrantFiled: February 12, 2016Date of Patent: August 16, 2016Assignee: Sequoia Sciences, Inc.Inventors: Gary Eldridge, Steven M Martin
-
Patent number: 9416371Abstract: Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parastic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount effective to elicit or stimulate a cell mediated immune response. The epidermis may be mechanically disrupted prior to, at the same time, or immediately after the administration of the vaccine. The vaccine can be used to induce immunity against a pathogen, such as a virus, bacteria, or parasite, or against a cancer in a subject that has or is at risk of developing cancer.Type: GrantFiled: January 27, 2014Date of Patent: August 16, 2016Assignee: TremRx, Inc.Inventors: Thomas S. Kupper, Luzheng Lisa Liu, Rachel A. Clark
-
Patent number: 9408897Abstract: Nucleic acid molecules that encode a protein comprising at least one epitope of membrane IgE free of epitopes present on the serum IgE, including proteins that further comprise non-IgE T cell helper epitope are disclosed. Vaccines, vectors and host cells that comprise such nucleic acid molecules are disclosed. Isolated proteins, including haptenized proteins, comprising at least one epitope of membrane IgE free of epitopes present on the serum IgE, including proteins that further comprise non-IgE T cell helper epitope are disclosed. Vaccines that comprise and methods of making such proteins and antibodies that specifically bind to such proteins are disclosed. Vaccines that comprise killed or inactivated cells or particles are disclosed. Methods of treating and preventing IgE mediated allergic disease or condition are disclosed.Type: GrantFiled: October 15, 2013Date of Patent: August 9, 2016Assignee: The Trustees of the University of PennsylvaniaInventors: Arnold I. Levinson, Sandra Calarota, David B. Weiner, Miguel Otero
-
Patent number: 9404851Abstract: The present invention relates to methods of spectrophotometric determination of the presence of particular substances in a complex mixture of compounds. This invention relates to methods for determining the concentration of various components of complex biological samples including the determination of the concentration of polyoxyethylene containing compounds including polysorbate in protein containing samples as well as determining the ratio of drug to antibody ratios in antibody-drug conjugate solutions.Type: GrantFiled: July 9, 2015Date of Patent: August 2, 2016Assignee: C Technologies IncInventor: I-Tsung Shih
-
Patent number: 9393273Abstract: A method of treating ulcerative colitis or Crohn's disease in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells from a placenta or adipose tissue, thereby treating the ulcerative colitis or Crohn's disease.Type: GrantFiled: May 26, 2009Date of Patent: July 19, 2016Assignee: Pluristem Ltd.Inventor: Moran Meiron
-
Patent number: 9388226Abstract: The invention relates to citrulline peptides with anti-inflammatory properties. The invention also relates to an in vitro model for activation of macrophages, induced by immune complexes between specified IgG of rheumatoid arthritis and their citrulline targets.Type: GrantFiled: May 3, 2007Date of Patent: July 12, 2016Assignee: Universite Paul SabatierInventors: Cyril Clavel, Mireille Sebbag, Maria Leonor Nogueira, Guy Serre
-
Patent number: 9381229Abstract: The present invention relates to an APJ receptor agonist or an apelinomimetic for use in the treatment or the prevention of a dysfunction associated with aging.Type: GrantFiled: November 27, 2012Date of Patent: July 5, 2016Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PAUL SABATIER TOULOUSE IIIInventors: Philippe Valet, Cedric Dray, Claude Knauf, Oksana Kunduzova, Isabelle Castan-Laurell
-
Patent number: 9332741Abstract: This invention relates transgenic animals that overexpress TL1A in a tissue specific manner to model inflammatory bowel disease (IBD), such as colitis, Crohn's disease and ulcerative colitis, fibrosis, and related inflammatory diseases and conditions. TL1A transgenic animals constitutively express both TL1A and GFP in lymphoid and myeloid cell lineages, allowing convenient identification and sorting of immune cells involved in IBD disease progression, such as T-cells, antigen presenting cells (APC), and dendritic cells (DC). TL1A transgenic animals may be induced to exhibit gross fibrosis, or isolated cells may be implanted into immunodeficient mice to establish colitis.Type: GrantFiled: May 8, 2014Date of Patent: May 10, 2016Assignee: Cedars-Sinai Medical CenterInventors: David Q. Shih, Stephan R. Targan
-
Patent number: 9327009Abstract: The present invention relates to synthetic peptide inhibitors (Seq ID No. 67-71) useful as anti-HIV therapeutics. The invention also relates to a novel screening method for screening anti-HIV molecules. The present invention relates to a synthetic peptide useful as anti-HIV therapeutic. The invention also relates to a novel screening method for screening of anti-HIV therapeutics. In particular, the present invention relates to reporter gene constructs for the detection of the HIV Nef and host ASK1 protein interaction. Furthermore, the invention relates to a functional interaction for Nef-ASK1 proteins prepared in a recombinant manner, a method for identifying of Nef-ASK1 interaction which causes activation of pathway to activate apoptosis presumably causing immune evasion for HIV in infected cells.Type: GrantFiled: March 1, 2013Date of Patent: May 3, 2016Assignee: Council of Scientific and Industrial ResearchInventors: Raj Kamal Tripathi, Balawant Kumar, Ravishankar Ramachandran, Jitendra Kumar Tripathi, Smriti Bhadauria, Jimut Kanti Ghosh
-
Patent number: 9303080Abstract: The present invention provides for nucleic acids improved for the expression of interleukin-15 (IL-15) in mammalian cells. The invention further provides for methods of expressing IL-15 in mammalian cells by transfecting the cell with a nucleic acid sequence comprising a codon optimized IL-15 sequence. The present invention further provides expression vectors, and IL-15 and IL 15 receptor alpha combinations (nucleic acid and protein) that increase IL-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of IL-15 after DNA, RNA or protein administration in a subject (e.g. a mammal, a human).Type: GrantFiled: January 12, 2007Date of Patent: April 5, 2016Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services, National Institutes of HealthInventors: Barbara K. Felber, George N. Pavlakis
-
Patent number: 9289478Abstract: The present invention relates to novel formulations of tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules as vaccines for the use in immunotherapeutic methods. In particular, the present invention relates to formulations for the immunotherapy of cancer, in particular renal and brain cancer, in particular glioma, especially glioblastoma cancer. The present invention furthermore relates to vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: April 23, 2009Date of Patent: March 22, 2016Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Peter Lewandrowski, Christian Flohr
-
Patent number: 9289471Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.Type: GrantFiled: April 16, 2014Date of Patent: March 22, 2016Assignee: National Jewish HealthInventor: Carl W. White
-
Patent number: 9283267Abstract: The present invention relates to novel formulations of tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules as vaccines for the use in immunotherapeutic methods. In particular, the present invention relates to formulations for the immunotherapy of cancer, in particular renal and brain cancer, in particular glioma, especially glioblastoma cancer. The present invention furthermore relates to vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: January 9, 2012Date of Patent: March 15, 2016Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Peter Lewandrowski, Christian Flohr
-
Patent number: 9273122Abstract: The use of monoclonal antibodies specific for respiratory syncytial virus (RSV). Specifically, to a monoclonal antibody IgG2A secreted by the cell line of 8A4/G9 hybridoma specifically directed to the M2-1 viral antigen, which is associated with the nucleocapside of the virus. The antibodies can be used for assays for the detection and/or determination of RSV infection. The antibodies are in the pure state and do not contain any other contaminating biological material. A method for preventing and treating the infection caused by respiratory syncytial virus (RSV) in a given host is provided, including the administration of a composition containing the monoclonal antibodies secreted by the 8A4/G9 hybridoma in sufficient doses to prevent the disease. The antibody can be humanized in order to minimize the possibility of an immune response against the same in the patient.Type: GrantFiled: November 23, 2012Date of Patent: March 1, 2016Assignee: Pontificia Universidad Catolica de ChileInventors: Alexis Mikes Kalergis Parra, Susan Marcela Bueno Ramirez, Jorge Eugenio Mora Alarcon, Roberto Sebastian Gomez Johnson
-
Patent number: 9271899Abstract: Compositions and methods of use for desensitizing a subject to an allergen via regions of the oral mucosa are provided.Type: GrantFiled: May 2, 2011Date of Patent: March 1, 2016Assignee: Allovate, LLCInventor: Cedric Francois
-
Patent number: 9265816Abstract: This invention provides mutated WT1 peptides SGQAYMFPNAPYLPSCLES (SEQ ID No:41) and QAYMFPNAPYLPSCL (SEQ ID No:42), immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.Type: GrantFiled: April 10, 2007Date of Patent: February 23, 2016Assignee: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: David A. Scheinberg, Rena May
-
Patent number: 9266930Abstract: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare Plasmodium falciparum epitopes, and to develop epitope-based vaccines directed towards malaria. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of malaria. In particular, this application discloses isolated peptides comprising oligopeptides, for example the oligopeptide GVSENIFLK, or isolated peptides conjugated with T helper peptides that are used as antigens in epitope-based vaccines to prevent and/or treat malaria.Type: GrantFiled: September 3, 1999Date of Patent: February 23, 2016Assignee: Epimmune Inc.Inventors: Alessandro Sette, John Sidney, Scott Southwood, Brian D. Livingston, Robert Chestnut, Denise Marie Baker, Esteban Celis, Ralph T. Kubo, Howard M. Grey
-
Patent number: 9248179Abstract: Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.Type: GrantFiled: June 23, 2011Date of Patent: February 2, 2016Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Xianfu Wu, Charles E. Rupprecht, Ivan V. Kuzmin
-
Patent number: 9241968Abstract: The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumor agents.Type: GrantFiled: September 11, 2009Date of Patent: January 26, 2016Assignee: Lytix Biopharma ASInventors: Bengt Erik Haug, Jon Amund Eriksen, John Sigurd Svendsen, Oystein Rekdal
-
Patent number: 9243064Abstract: The present invention provides novel antibody vaccine conjugates and methods of using the same to induce a cytotoxic T cell (CTL) response. In a particular, embodiment, the vaccine conjugate includes a human chorionic gonadotropin beta subunit (?hCG) antigen linked to an anti-mannose receptor (MR) antibody.Type: GrantFiled: January 30, 2004Date of Patent: January 26, 2016Assignee: Celldex Therapeutics Inc.Inventors: Tibor Keler, Michael Endres, Lizhen He, Venky Ramakrishna
-
Patent number: 9234028Abstract: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: GrantFiled: August 1, 2013Date of Patent: January 12, 2016Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Ray Camphausen, Brent Morse, Stuart Emanuel, David Fabrizio
-
Patent number: 9226934Abstract: The present invention is directed to an anti-cancer drug containing an anti-MFG-E8 antibody as an active ingredient, and to an anti-cancer drug which employs an anti-MFG-E8 antibody in combination with a cancer therapy employing an anti-cancer agent other than the anti-MFG-E8 antibody.Type: GrantFiled: April 28, 2009Date of Patent: January 5, 2016Assignee: THE UNIVERSITY OF TOKYOInventors: Hideaki Tahara, Masahisa Jinushi
-
Patent number: 9221876Abstract: The invention provides compositions comprising immunogenic fragments of ApoB-100 for eliciting an immune response in a subject or vaccinating a subject, so as to treat, prevent, 5 inhibit and/or reduce symptoms of kidney diseases in the subject. The compositions include immunogenic fragments of ApoB-100, CD8+ T cells activated with immunogenic fragments of ApoB-100 or a combination thereof.Type: GrantFiled: November 6, 2012Date of Patent: December 29, 2015Assignee: CardioVax, LLCInventors: Kuang-Yuh Chyu, Prediman K. Shah, Paul Dimayuga
-
Patent number: 9216156Abstract: The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an immune response against a gp41 protein or a human immunodeficiency virus (HIV).Type: GrantFiled: March 2, 2007Date of Patent: December 22, 2015Assignees: MYMETICS CORPORATION, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), PEVION BIOTECH LTD.Inventors: Sylvain Fleury, Morgane Bomsel, Rinaldo Zurbriggen
-
Patent number: 9211345Abstract: A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof.Type: GrantFiled: December 2, 2014Date of Patent: December 15, 2015Assignee: University of Georgia Research Foundation, Inc.Inventors: Geert-Jan Boons, Therese Buskas, Sampat Ingale, Margaretha Wolfert
-
Patent number: 9187568Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.Type: GrantFiled: May 7, 2010Date of Patent: November 17, 2015Assignee: STALLERGENES S.A.Inventors: Thierry Batard, Philippe Moingeon, Laurent Mascarell, Aline Zimmer, Emmanuel Nony
-
Patent number: 9180204Abstract: Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilization. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135.Type: GrantFiled: June 30, 2014Date of Patent: November 10, 2015Assignee: Novartis AGInventor: Mario Contorni
-
Patent number: 9180164Abstract: A pharmaceutical composition includes a synthetic peptide consisting of about 10 to about 50 amino acids and having an amino acid sequence substantially homologous to consecutive amino acids of a portion of the cytoplasmic domain of at least one of ?v?3 integrin or VEGFR2 that includes a tyrosine residue, the amino acid sequence of the peptide including a phosphorylated tyrosine residue or a ?-carboxyglutamic acid residue that is substituted for a corresponding tyrosine residue of the portion of the cytoplasmic domain of ?v?3 integrin or VEGFR2.Type: GrantFiled: December 14, 2012Date of Patent: November 10, 2015Assignee: The Cleveland Clinic FoundationInventors: Tatiana Byzova, Ganapati H. Mahabaleshwar, Weiyi Feng
-
Patent number: 9180175Abstract: A Thomsen-Friedenreich disaccharide-containing glycopeptide purified from cod fish of approximately 100 kDa (designated TFD100) and methods of using the same in the suppression of cancer metastasis is disclosed.Type: GrantFiled: March 27, 2012Date of Patent: November 10, 2015Assignee: UNIVERSITY OF MARYLAND, BALTIMOREInventors: Hafiz Ahmed, Prasun Guha, Engin Kaptan, Gerardo Vasta, Gargi Bandyopadhyaya
-
Patent number: 9176150Abstract: The invention relates to neuromodulatory oligomers of the amyloid-?(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents. The invention further relates to derivatives of the oligomers and oligomers based on abbreviated forms of the amyloid-?(1-42) proteins, the production and use thereof.Type: GrantFiled: August 1, 2011Date of Patent: November 3, 2015Assignee: AbbVie Deutschland GmbH & Co. KGInventors: Heinz Hillen, Andreas Striebinger, Carsten Krantz, Achim Moeller, Reinhold Mueller
-
Patent number: 9169316Abstract: The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.Type: GrantFiled: June 13, 2007Date of Patent: October 27, 2015Assignees: Centre National de la Recherche Scientifique-CNRS, INSERM (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix Marseille, Universite de Montpellier, Institut Regional du Cancer de Montpellier-Val d'Aurelle, Institut Paoli CalmettesInventors: Daniel Baty, Ghislaine Behar, Martine Chartier, André Pelegrin, Jean-luc Teillaud, Isabelle Teulon
-
Patent number: 9168290Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin monocysteinic active site in a reduced state and optionally further contains a reducing system.Type: GrantFiled: March 17, 2014Date of Patent: October 27, 2015Assignee: OrPro Therapeutics, Inc.Inventor: Peter B. Heifetz
-
Patent number: 9169314Abstract: The invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the Ixodes ricinus arthropod tick, during the slow-feeding phase of the blood meal have, said polynucleotide and related polypeptide may be used in different constructions and for different applications which are also included in the present invention.Type: GrantFiled: October 1, 2012Date of Patent: October 27, 2015Assignee: BIOXODES SAInventors: Edmond Godfroid, Yves Decrem, Luc Vanhamme, Alex Bollen, Gerard Leboulle
-
Patent number: 9163063Abstract: Provided herein are peptides and nanoparticles conjugates thereof useful for the treatment of diseases and disorders mediated by GIPC/synectin, such as cancer.Type: GrantFiled: October 23, 2013Date of Patent: October 20, 2015Assignees: Trustees of Darmouth College, Mayo Foundation for Medical Education and ResearchInventors: Debabrata Mukhopadhyay, Priyabrata Mukherjee, Mark Spaller
-
Patent number: 9161974Abstract: Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.Type: GrantFiled: May 23, 2011Date of Patent: October 20, 2015Assignee: ADURO BIOTECH, INC.Inventors: Thomas W. Dubensky, Dirk G. Brockstedt, Meredith Leong, Keith S. Bahjat
-
Patent number: 9155779Abstract: The present invention relates to the use of Yersinia outer protein M (YopM)in the prevention and/or treatment of psoriasis by cutaneous, intradermalor subcutaneous administration. In particular, the present invention relates to the use of YopM in the treatment of plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, arthritis psoriasis.Type: GrantFiled: February 24, 2012Date of Patent: October 13, 2015Assignee: WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTERInventors: Christian Rueter, Alexander Schmidt
-
Patent number: 9150664Abstract: The present invention relates to a binding molecule comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope clusters of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.Type: GrantFiled: November 15, 2012Date of Patent: October 6, 2015Assignees: AMGEN RESEARCH (MUNICH) GMBH, BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Peter Kufer, Tobias Raum, Patrick Hoffmann, Roman Kischel, Ralf Lutterbuese, Doris Rau, Paul Adam, Eric Borges, Barbara Hebeis, Susanne Hipp
-
Patent number: 9150643Abstract: Methods for treating diabetes by administering an inhibitor of GDF-8, or a related member of Transforming Growth Factor-beta (TGF-?) superfamily of structurally-related growth factors (e.g., GDF-11) are disclosed. Also disclosed are methods for upregulating expression of hexose transporters, such as GLUT4 and GLUT1, in a subject by administering an inhibitor of GDF-8. Also disclosed are methods for increasing glucose uptake by cells in a subject, by administering an inhibitor of GDF-8.Type: GrantFiled: February 14, 2008Date of Patent: October 6, 2015Assignee: Scidera, Inc.Inventors: Li-Fang Liang, Stavros Topouzis
-
Patent number: 9149216Abstract: A system and method for measuring one or more light-absorption related blood analyte concentration parameters of a mammalian subject, is disclosed. In some embodiments, the system comprises: a) a photoplethysmography (PPG) device configured to effect a PPG measurement by illuminating skin of the subject with at least two distinct wavelengths of light and determining relative absorbance at each of the wavelengths; b) a dynamic light scattering measurement (DLS) device configured to effect a DLS measurement of the subject to rheologically measure a pulse parameter of the subject; and c) electronic circuitry configured to: i) temporally correlating the results of the PPG and DLS measurements; and ii) accordance with the temporal correlation between the PPG and DLS measurements, assessing value(s) of the one or more light-absorption related blood analyte concentration parameter(s).Type: GrantFiled: October 1, 2014Date of Patent: October 6, 2015Assignee: Oxitone Medical Ltd.Inventors: Leon Eisen, Alexander Kaminsky, Ilya Fine
-
Patent number: 9144595Abstract: One embodiment of a therapeutic composition comprises one or more APLs, e.g., APL A12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a Th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of A12 analog peptide. Another embodiment includes a method for generating functional T regulatory cells, the method including administering a therapeutic amount of APL A12 to a RA patient.Type: GrantFiled: October 1, 2013Date of Patent: September 29, 2015Assignee: University of Tennessee Research FoundationInventors: Arnold E. Postlethwaite, Andrew Ho Kang, Linda K. Myers
-
Patent number: 9132178Abstract: The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as lung carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against lung and other cancers.Type: GrantFiled: June 13, 2010Date of Patent: September 15, 2015Assignee: Immunotope, Inc.Inventor: Ramila Philip
-
Patent number: 9125849Abstract: The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 42, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.Type: GrantFiled: November 25, 2011Date of Patent: September 8, 2015Assignee: ONCOTHERAPY SCIENCE, INC.Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Osawa, Sachiko Yoshimura, Tomohisa Watanabe, Gaku Nakayama
-
Patent number: 9127044Abstract: The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.Type: GrantFiled: February 14, 2012Date of Patent: September 8, 2015Assignee: NOVARTIS AGInventors: Philipp Krastel, Brigitta-Maria Liechty, Josef Gottfried Meingassner, Esther Schmitt, Erwin Paul Schreiner
-
Patent number: 9127050Abstract: A number of ?-hemolytic streptococci polynucleotides and polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, are described. Two or more of the polypeptides of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing infection caused by ?-hemolytic streptococci.Type: GrantFiled: July 16, 2013Date of Patent: September 8, 2015Assignees: Regents of the University of Minnesota, Wyeth LLCInventors: Ingrid Lea Scully, Annaliesa Sybil Anderson, Michael Hagen, Stephen Bruce Olmsted, Paul Patrick Cleary
-
Patent number: 9096659Abstract: The invention provides compositions and fusion proteins comprising a flagellin adjuvant and a Pseudomonas aeruginosa antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against P. aeruginosa (e.g., to prevent and/or treat P. aeruginosa infection).Type: GrantFiled: March 16, 2010Date of Patent: August 4, 2015Assignee: Wake Forest University Health SciencesInventors: Steven B. Mizel, Daniel J. Wozniak, Eric T. Weimer
-
Patent number: 9081019Abstract: The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95.Type: GrantFiled: June 6, 2013Date of Patent: July 14, 2015Assignee: Laboratory Corporation of America HoldingsInventors: Jeff Sperinde, John William Winslow, Xueguang Jin, Gerald J. Wallweber
-
Patent number: 9074000Abstract: The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels.Type: GrantFiled: April 2, 2012Date of Patent: July 7, 2015Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.Inventors: David A. Scheinberg, Tao Dao, Cheng Liu, Su Yan
-
Patent number: 9061002Abstract: Use of flagellins from the genus Marinobacter as vaccine adjuvants. This invention is based on the use of two recombinant flagellins, F and FR, from the species Marinobacter algicola (DG893T strain), as vaccine adjuvants capable of developing a specific immune response, against peptides or proteins fused to said flagellins, or administered unfused jointly with the flagellins. This invention also describes new combined vaccination strategies, based on the two Marinobacter algicola flagellins and the Salmonella typhimurium flagellin.Type: GrantFiled: February 2, 2010Date of Patent: June 23, 2015Assignee: INSTITUTO NACIONAL DE INVESTIGACIÓN TECNOLOGÍA AGRARIA Y ALIMENTARIA (INIA)Inventor: Eduardo Gómez Casado